Histone deacetylase inhibitors suppress aggressiveness of head and neck squamous cell carcinoma via histone acetylation-independent blockade of the EGFR-Arf1 axis

Medicine & Life Sciences

• ADP-Ribosylation Factor 1 100%
• Histone Deacetylase Inhibitors 68%
• Squamous Cell Carcinoma of Head and Neck 64%
• Acetylation 61%
• ErbB Receptors 55%
• Histones 54%
• Histone Deacetylases 33%
• Receptor Protein-Tyrosine Kinases 15%
• Cell Membrane 10%
• Monomeric GTP-Binding Proteins 8%
• Nucleic Acid Regulatory Sequences 8%
• Proteome 7%
• Immunoprecipitation 7%
• Cell- and Tissue-Based Therapy 6%
• Cell Movement 5%
• Proteins 5%
• Phosphorylation 5%
• Western Blotting 4%
• Neoplasms 4%
• DNA 4%
• Survival 4%
• Wounds and Injuries 3%
• Therapeutics 1%